| Literature DB >> 34160593 |
Tim Raine1, Bram Verstockt2,3, Uri Kopylov4,5, Konstantinos Karmiris6, Rimma Goldberg7, Raja Atreya8, Johan Burisch9, John Burke10, Pierre Ellul11, Charlotte Hedin12,13, Stefan D Holubar14, Konstantinos Katsanos15, Triana Lobaton16, Carsten Schmidt17, Garret Cullen18.
Abstract
Inflammatory bowel disease is a chronic disease with variable degrees of extent, severity, and activity. A proportion of patients will have disease that is refractory to licensed therapies, resulting in significant impairment in quality of life. The treatment of these patients involves a systematic approach by the entire multidisciplinary team, with particular consideration given to medical options including unlicensed therapies, surgical interventions, and dietetic and psychological support. The purpose of this review is to guide clinicians through this process and provide an accurate summary of the available evidence for different strategies.Entities:
Keywords: Crohn’s disease; Inflammatory bowel disease; refractory; ulcerative colitis; unlicensed medication
Mesh:
Substances:
Year: 2021 PMID: 34160593 DOI: 10.1093/ecco-jcc/jjab112
Source DB: PubMed Journal: J Crohns Colitis ISSN: 1873-9946 Impact factor: 10.020